Mcbk s.c. Iwona Czajkowska Anna Podrazka Szczepaniak

The team at MCBK is investigating innovative anticoagulant approaches for patients with atrial fibrillation to lower the incidence of stroke and systemic embolism.

• Atrial fibrillation
• Stroke prevention
• Cardioembolic event risk reduction

Across 14 active studies and with 7 dedicated investigators, the site advances cardiovascular care for the local community.

Researchers are evaluating targeted therapies such as upadacitinib for rheumatoid arthritis and exploring new options for chronic spontaneous urticaria and primary Sjögren’s disease.

• Rheumatoid arthritis
• Chronic spontaneous urticaria
• Primary Sjögren’s disease
• Atopic dermatitis

These investigations aim to improve symptom control and long‑term outcomes for patients with immune‑mediated disorders.

The centre is conducting studies on chronic obstructive pulmonary disease (COPD) to assess treatments that reduce the frequency and severity of exacerbations.

• Chronic obstructive pulmonary disease (COPD)
• Exacerbation reduction
• Respiratory viral infection prevention

By testing novel biologics and combination vaccines, the site seeks to enhance breathing health for patients with persistent lung disease.

Clinical work focuses on severe dermatologic conditions, including oral agents for plaque psoriasis and topical strategies for atopic dermatitis, as well as therapies for nummular eczema and hidradenitis suppurativa.

• Plaque psoriasis
• Atopic dermatitis
• Nummular eczema
• Hidradenitis suppurativa
• Vitiligo

The goal is to provide effective, lasting relief for patients suffering from chronic skin disorders.

Studies include evaluation of immune responses to a combined COVID‑19 and influenza vaccine in older adults, aiming to ensure protective immunity against both viruses.

• COVID‑19
• Influenza
• SARS‑CoV‑2 variant response

These trials support the development of broader preventive measures for viral respiratory illnesses.